EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

Which recent changes belong on the procurement committee’s agenda?

Dose Diligence research deskSection 04 · Page 2 of 17Last updated 17 Nov 2026
DateDevelopment and statusBuyers affectedRecommended immediate response
November 9, 2026FDA requires GLP-1 labelling changes concerning a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION.All clinical programmes and dispensing partnersMedical director: review counselling, escalation and partner materials. (fda.gov)
November 10, 2026FTC’s Hims & Hers case records an amended complaint; five additional states joined the privacy and billing litigation. These remain allegations, not adjudicated findings.Telehealth platforms, subscription clinics and integrated access vendorsCompliance: review data sharing, charging triggers and cancellation workflows. (ftc.gov)
October 30, 2026HHS publishes notice of a draft/interim enforcement-discretion policy for specified peptide substances—not a general GLP-1 compounding permission.Clinics receiving peptide-expansion proposalsCounsel: reject extrapolation beyond the substances and conditions actually listed. (govinfo.gov)
September 18, 2026FDA’s Empower Pharmacy warning letter challenges apparently copied GLP-1 preparations and supporting patient-difference documentation.Clinics relying on patient-specific compoundingAudit prescribing templates and evidence supporting formulation changes. (fda.gov)
August 27, 2026; semaglutide opinion revised September 1Fifth Circuit opinions affirm judgments supporting FDA’s tirzepatide and semaglutide shortage decisions.Buyers relying on litigation to preserve shortage-era supplyRequire the actual order behind any claimed litigation protection. (ca5.uscourts.gov)
August 12, 2026FDA letter addresses compounded GLP-1 multidose-vial labelling, dosing confusion and use beyond the customary post-puncture period.Clinical, procurement and finance teamsReconcile vial size, discard instructions and usable supply before accepting quotes. (azbn.gov)
August 6, 2026FDA grants an additional year of specified DSCSA exemptions for qualifying small dispensers, through November 27, 2027.Pharmacy owners and clinic-stock supply chainsDocument eligibility and the obligations that remain applicable. (fda.gov)
July 1, 2026Medicare GLP-1 Bridge launches; eligible beneficiaries can access selected products for a $50 monthly copay, through December 31, 2027.Clinics serving Medicare beneficiariesAdd eligibility screening and pharmacy claims-routing tests. (cms.gov)
April 30 announcement; May 1, 2026 publicationFDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.Buyers considering outsourcing facilitiesTreat as a proposal, not a newly effective blanket ban or temporary permission. (fda.gov)
Explore the table row by row

A working view of the research

November 9, 2026

Development and status
FDA requires GLP-1 labelling changes concerning a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION.
Buyers affected
All clinical programmes and dispensing partners
Recommended immediate response
Medical director: review counselling, escalation and partner materials. (fda.gov)

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential?trk=public_post_comment-text&utm_source=openai
  2. ftc.gov · Source 2 ↗https://www.ftc.gov/legal-library/browse/cases-proceedings/hims-hers-health-inc-ftc-v-timeline-item-2026-11-10
  3. govinfo.gov · Source 3 ↗https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
  4. fda.gov · Source 4 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026?utm_source=openai
  5. ca5.uscourts.gov · Source 5 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
  6. azbn.gov · Source 6 ↗https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials
  7. fda.gov · Source 7 ↗https://www.fda.gov/media/194424/download
  8. cms.gov · Source 8 ↗https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications?utm_source=openai
  9. fda.gov · Source 9 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
Section sources →